ANI Pharmaceuticals (NASDAQ:ANIP) posted its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported $1.29 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.17 by $0.12, MarketWatch Earnings reports. ANI Pharmaceuticals had a return on equity of 27.76% and a net margin of 0.06%. The company had revenue of $50.70 million during the quarter, compared to analyst estimates of $50.97 million. During the same quarter last year, the company earned $1.11 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. ANI Pharmaceuticals updated its FY18 guidance to $4.80-5.27 EPS.
ANIP stock traded up $2.20 on Tuesday, reaching $53.78. 3,074 shares of the company traded hands, compared to its average volume of 68,339. ANI Pharmaceuticals has a one year low of $48.51 and a one year high of $74.70. The company has a quick ratio of 2.89, a current ratio of 3.84 and a debt-to-equity ratio of 1.08. The firm has a market cap of $613.94 million, a PE ratio of 15.01 and a beta of 2.64.
Hedge funds have recently bought and sold shares of the stock. Aperio Group LLC increased its position in ANI Pharmaceuticals by 21.3% during the 2nd quarter. Aperio Group LLC now owns 5,799 shares of the specialty pharmaceutical company’s stock valued at $387,000 after buying an additional 1,019 shares in the last quarter. Strs Ohio boosted its stake in ANI Pharmaceuticals by 17.3% during the 2nd quarter. Strs Ohio now owns 12,200 shares of the specialty pharmaceutical company’s stock valued at $814,000 after purchasing an additional 1,800 shares during the last quarter. Cadence Capital Management LLC boosted its stake in ANI Pharmaceuticals by 83.3% during the 2nd quarter. Cadence Capital Management LLC now owns 46,108 shares of the specialty pharmaceutical company’s stock valued at $3,080,000 after purchasing an additional 20,947 shares during the last quarter. Phocas Financial Corp. purchased a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $2,788,000. Finally, Boston Partners purchased a new stake in ANI Pharmaceuticals during the 2nd quarter valued at $3,144,000. 61.10% of the stock is owned by institutional investors.
ANIP has been the subject of a number of analyst reports. BidaskClub lowered ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 19th. Cantor Fitzgerald set a $74.00 price objective on ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, October 3rd. ValuEngine lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, October 8th. Finally, Canaccord Genuity set a $75.00 price objective on ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 16th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $72.67.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/11/06/ani-pharmaceuticals-anip-issues-earnings-results-beats-estimates-by-0-12-eps.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
See Also: Why is the ex-dividend date different from the record date?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.